- Build and oversee the Biostatistics and Statistical Programming functions and quality systems.- Core team member for product portfolio and clinical/RWE programs. Member of Development Leadership Team. - Global regulatory interactions early to late phase- Business owner of company-wide computing environment with fit-for-purpose analytical applications; key stakeholder for analytical vendors and platforms evaluation and integration.- Alumis is a precision medicine company with the mission to transform the lives of patients with autoimmune diseases.

Founding Board Member, Secretary to the Board (2018- 2023)President-Elect (2024)Annual Conference Chair and Chair of Steering Committee (2024)BBSW is a 501C(3) organization in the San Francisco Bay Area, to promote connection, leadership, growth and impact of the statistics and quantitative science community. www.bbsw.org

Chair and co-founded the Partnership for Clinical Research and Statistics (PCRS) at ASA. PCRS serves as the primary platform at the ASA for collaborative partnership and programs with professional clinical organizations and FDA.

Established as part of the 2022 ASA Presidential Initiatives, CIR at ASA provides resources for industry statisticians and data scientists to successfully advocate for the discipline.https://community.amstat.org/caucusofindustryrepresentatives/homehttps://magazine.amstat.org/blog/category/caucus-of-industry-representatives/

ASA Board Member to manage financial committees (investment, audit, budget, development). Appointed for the term 2020-2023.

Vice Chair of District 6, American Statistical Association Council of Governing Board (ASA-COCGB). The District 6 consists of 15 chapters from 11 states with about 2,000 members on the west coast of US. Appointed for 2018-2019, and then elected for the term 2020-2022.

Co-Founder of DahShu, a 510(c)(3) non-profit organization that promotes research and education in data sciences. Please visit us at:www.dahshu.orghttps://www.linkedin.com/company/DahShu

Responsibilities: ✓ Functional head overseeing the department of Statistics, Clinical Data Management & Data Science, and end-to-end analytical pipeline.✓ Built the team from ground up. ✓ Built the functional quality system from group up. ✓ Strategic thinker and key stakeholder in business development and strategy for all clinical programs including Breast Cancer and COVID.✓ Team supports the large-scale platform trials such as I-SPY Breast Cancer and I-SPY COVID using master protocols in phase 1 and phase 2 drug development to rapidly develop targeted therapies. ✓ Built relationships with the I-SPY Consortium Leadership and collaborated on publicationsand congress presentations as co-authors/presenter.About Quantum Leap Healthcare Collaboratives (QLHC): QLHC is the sponsor for the I-SPY trials (Breast Cancer and COVID), BreastCancerTrials.org, and CTMatch, integrating high-impact clinical research with patient care. - Accelerate the development of safe, effective, personalized treatment, detection and prevention options and improve the delivery of clinical care. - The core of the I-SPY program is the ground-breaking I-SPY 2 platform trial using master protocol, with advanced analytical and operational pipelines.

• Build, lead and manage a team of biostatisticians/data scientists and statistical programmers as the functional head of Clinical Biostatistics and Statistical Programming.• Direct and oversee statistical activities in support of clinical studies, algorithm development, preparation of final study reports, and conference abstracts and peer-reviewed manuscripts. • Strategic and agile leader with influence in the local and national statistical community.• Drive functional process needs and standardization, and define and implement best practices and departmental policies.• Define and justify functional headcount requirements, recruiting and hiring decisions. Onboard new hires.

• Direct a team of biostatisticians and statistical programmers; oversee statistical activities in support of clinical studies, algorithm development, preparation of final study reports, and conference abstracts and peer-reviewed manuscripts.• Represent the statistics function for clinical programs.• Drive functional process needs and standardization, and defining and implementing best practices for Clinical Biostatistics.• Strategic and emerging leader with influence in the local and national statistical community.

• Represent the statistics function on project teams for clinical development programs, providing strategic input to the study design and clinical plans. • Strategic leader within the company. Able to communicate effectively throughout all levels of organization, and work effectively in multi-disciplinary teams. • Demonstrated success in interacting with and exerting significant influence on internal and external collaborators on study design, analysis methods, and interpretation of study results.• Manage and oversee statistical programming activities.

• Develop and implement of U.S. and International Medical Affairs strategies.• Support design, analysis and publication of results from Medical Affairs studies; domestic and international reimbursement submissions; planning and development of publications, product messaging, marketing materials, and education and training materials.• Create networks with external clinical and statistical collaborators. • Influence decisions to ensure quality of study designs and analyses, appropriateness of inferences and conclusions, and alignment with the company strategic interests.

Lead statistician on clinical studies for IVD product registration, FDA 510(k) submissions, and post-market medical affairs activities. Novartis Diagnostics Business Unit was sold to Grifols Diagnostics Solution in Feb. 2014.

Mostly non-clinical statistical work.Lead statistician for the analysis pipeline for the Axiom SNP calling algorithm and implementation using Perl and R. Working with product scientists on DOE to optimize automation processes.